Skip to main content

Vtama FDA Approval History

Last updated by Judith Stewart, BPharm on Dec 17, 2024.

FDA Approved: Yes (First approved May 23, 2022)
Brand name: Vtama
Generic name: tapinarof
Dosage form: Cream
Company: Organon Pharmaceuticals
Treatment for: Plaque Psoriasis, Atopic Dermatitis

Vtama (tapinarof) is a topical aryl hydrocarbon receptor (AhR) modulating agent used for the treatment of plaque psoriasis and atopic dermatitis.

Development timeline for Vtama

DateArticle
Dec 16, 2024Approval FDA Approves Vtama (tapinarof) Cream for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
May 24, 2022Approval FDA Approves Vtama (tapinarof) Cream for the Treatment of Plaque Psoriasis in Adults
Mar 25, 2022Dermavant Showcases New Long-Term Durability and Tolerability Data from Phase 3 PSOARING 3 Trial of Tapinarof Cream for Adults with Plaque Psoriasis at the 2022 AAD Annual Meeting
Sep  9, 2021Dermavant Announces First Patient Dosed in ADORING, its Pivotal Phase 3 Clinical Program for Tapinarof for the Topical Treatment of Atopic Dermatitis
Aug 10, 2021Dermavant Announces FDA Acceptance for Filing of New Drug Application (NDA) for Tapinarof Cream for the Treatment of Adults with Plaque Psoriasis
Jun  3, 2021Dermavant Submits New Drug Application (NDA) to FDA for Tapinarof Cream for the Treatment of Adults with Plaque Psoriasis
Jun  5, 2019Dermavant Sciences Announces First Patient Dosed in PSOARING, its Pivotal Phase 3 Clinical Program for Tapinarof for the Topical Treatment of Plaque Psoriasis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.